Special Issue

COVID-19 Vaccination: Clinical Response, Influencing Factors, Development Prospects

Message from the Guest Editors

The world is in the midst of the COVID-19 pandemic and is expecting vaccines to be game changers. Four months after COVID-19 vaccination beginning in many countries, however, many challenges remain, as listed below:

- Accelerating the development of safe and effective vaccines against COVID-19;
- Population prioritized for vaccination and fair and equitable allocation of vaccines for all countries;
- Safety and adverse events seen after clinical trial;
- Effective pharmacovigilance strategies;
- COVID-19 variants and vaccines;
- Length of effectiveness of vaccines;
- Influencing factors in vaccine response;
- Clinical responses;
- Chances of getting COVID-19 after being fully vaccinated:
- Spreading COVID-19 after being vaccinated;
- Pros and cons of vaccine types;
- Personalized use of vaccines according to patient profiles.

This Special Issue aims both to provide an overview of vaccines' mechanisms of action, clinical response, and safety and address clinical questions concerning personalized management of vaccination. Prof. Dr. Panayiotis G. Vlachoyiannopoulos

Guest Editors

Prof. Dr. Panayiotis G. Vlachoyiannopoulos

Medical School, National and Kapodistrian University of Athens, Laiko Hospital, 11527 Athens, Greece

Dr. Paraskevi Katsaounou

- Pulmonary Dept of First ICU Clinic, Evangelismos Hospital, 10676 Athens, Greece
- 2. School of Medicine, National and Kapodistrian University of Athens, 10561 Athens. Greece

Deadline for manuscript submissions

closed (25 May 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/87276

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

